These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9629473)

  • 21. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A novel dipeptide-based HIV protease inhibitor containing allophenylnorstatine.
    Abdel-Rahman HM; el-Koussi NA; Alkaramany GS; Youssef AF; Kiso Y
    Arch Pharm (Weinheim); 2004 Nov; 337(11):587-98. PubMed ID: 15540219
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic HIV protease inhibitors: design and synthesis of orally bioavailable, pyrazole P2/P2' cyclic ureas with improved potency.
    Han Q; Chang CH; Li R; Ru Y; Jadhav PK; Lam PY
    J Med Chem; 1998 Jun; 41(12):2019-28. PubMed ID: 9622543
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
    Ami E; Nakahara K; Sato A; Nguyen JT; Hidaka K; Hamada Y; Nakatani S; Kimura T; Hayashi Y; Kiso Y
    Bioorg Med Chem Lett; 2007 Aug; 17(15):4213-7. PubMed ID: 17537628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent inhibitors of the HIV-1 protease with good oral bioavailabilities.
    Sham HL; Zhao C; Marsh KC; Betebenner DA; Lin S; McDonald E; Vasavanonda S; Wideburg N; Saldivar A; Robins T
    Biochem Biophys Res Commun; 1995 Jun; 211(1):159-65. PubMed ID: 7779082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis, antiviral activity, and bioavailability studies of gamma-lactam derived HIV protease inhibitors.
    Hungate RW; Chen JL; Starbuck KE; Vacca JP; McDaniel SL; Levin RB; Dorsey BD; Guare JP; Holloway MK; Whitter W
    Bioorg Med Chem; 1994 Sep; 2(9):859-79. PubMed ID: 7712123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonpeptidic potent HIV-1 protease inhibitors: (4-hydroxy-6-phenyl-2-oxo-2H- pyran-3-yl)thiomethanes that span P1-P2' subsites in a unique mode of active site binding.
    Prasad JV; Para KS; Tummino PJ; Ferguson D; McQuade TJ; Lunney EA; Rapundalo ST; Batley BL; Hingorani G; Domagala JM
    J Med Chem; 1995 Mar; 38(6):898-905. PubMed ID: 7699705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protein structure-based design of potent orally bioavailable, nonpeptide inhibitors of human immunodeficiency virus protease.
    Reich SH; Melnick M; Davies JF; Appelt K; Lewis KK; Fuhry MA; Pino M; Trippe AJ; Nguyen D; Dawson H
    Proc Natl Acad Sci U S A; 1995 Apr; 92(8):3298-302. PubMed ID: 7724556
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Structure-based design of achiral, nonpeptidic hydroxybenzamide as a novel P2/P2' replacement for the symmetry-based HIV protease inhibitors.
    Randad RS; Lubkowska L; Silva AM; Guerin DM; Gulnik SV; Yu B; Erickson JW
    Bioorg Med Chem; 1996 Sep; 4(9):1471-80. PubMed ID: 8894104
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Structure-based design of novel HIV protease inhibitors: sulfonamide-containing 4-hydroxycoumarins and 4-hydroxy-2-pyrones as potent non-peptidic inhibitors.
    Thaisrivongs S; Janakiraman MN; Chong KT; Tomich PK; Dolak LA; Turner SR; Strohbach JW; Lynn JC; Horng MM; Hinshaw RR; Watenpaugh KD
    J Med Chem; 1996 Jun; 39(12):2400-10. PubMed ID: 8691434
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
    Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV protease inhibitory bis-benzamide cyclic ureas: a quantitative structure-activity relationship analysis.
    Wilkerson WW; Akamike E; Cheatham WW; Hollis AY; Collins RD; DeLucca I; Lam PY; Ru Y
    J Med Chem; 1996 Oct; 39(21):4299-312. PubMed ID: 8863807
    [TBL] [Abstract][Full Text] [Related]  

  • 34. HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent.
    Duffy JL; Rano TA; Kevin NJ; Chapman KT; Schleif WA; Olsen DB; Stahlhut M; Rutkowski CA; Kuo LC; Jin L; Lin JH; Emini EA; Tata JR
    Bioorg Med Chem Lett; 2003 Aug; 13(15):2569-72. PubMed ID: 12852968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of novel benzothiazolesulfonamides as potent inhibitors of HIV-1 protease.
    Nagarajan SR; De Crescenzo GA; Getman DP; Lu HF; Sikorski JA; Walker JL; McDonald JJ; Houseman KA; Kocan GP; Kishore N; Mehta PP; Funkes-Shippy CL; Blystone L
    Bioorg Med Chem; 2003 Nov; 11(22):4769-77. PubMed ID: 14556792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design of orally bioavailable, symmetry-based inhibitors of HIV protease.
    Kempf DJ; Marsh KC; Fino LC; Bryant P; Craig-Kennard A; Sham HL; Zhao C; Vasavanonda S; Kohlbrenner WE; Wideburg NE
    Bioorg Med Chem; 1994 Sep; 2(9):847-58. PubMed ID: 7712122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV proteinase inhibitors containing 2-aminobenzylstatine as a novel scissile bond replacement: biochemical and pharmacological characterization.
    Billich A; Charpiot B; Fricker G; Gstach H; Lehr P; Peichl P; Scholz D; Rosenwirth B
    Antiviral Res; 1994 Dec; 25(3-4):215-33. PubMed ID: 7710270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Nonpeptidic HIV protease inhibitors possessing excellent antiviral activities and therapeutic indices. PD 178390: a lead HIV protease inhibitor.
    Prasad JV; Boyer FE; Domagala JM; Ellsworth EL; Gajda C; Hamilton HW; Hagen SE; Markoski LJ; Steinbaugh BA; Tait BD; Humblet C; Lunney EA; Pavlovsky A; Rubin JR; Ferguson D; Graham N; Holler T; Hupe D; Nouhan C; Tummino PJ; Urumov A; Zeikus E; Zeikus G; Gracheck SJ; Erickson JW
    Bioorg Med Chem; 1999 Dec; 7(12):2775-800. PubMed ID: 10658583
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-735,524: the design of a potent and orally bioavailable HIV protease inhibitor.
    Dorsey BD; Levin RB; McDaniel SL; Vacca JP; Guare JP; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC
    J Med Chem; 1994 Oct; 37(21):3443-51. PubMed ID: 7932573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elucidating the inhibiting mode of AHPBA derivatives against HIV-1 protease and building predictive 3D-QSAR models.
    Huang X; Xu L; Luo X; Fan K; Ji R; Pei G; Chen K; Jiang H
    J Med Chem; 2002 Jan; 45(2):333-43. PubMed ID: 11784138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.